Litigation in the life sciences industry is often complicated by the involvement of multiple parties whose interests differ and alignments shift over the course of a trial. Further, the industry is one of the most sensitive and strategic out there when it comes to sharing and disclosing information. Thus lawyers practicing in this area need a heightened awareness of their professional ethical obligations to protect their clients' confidential information and of the tools and techniques available to develop appropriate safeguards.
To learn more about recent changes to lawyers' rules of professional conduct regarding maintaining clients' confidential information, especially as they affect life sciences litigation, join ReplyToSome Co-Founder Peter Norman at the Drug and Device Defense Forum. Sponsored by HB Litigation Conferences, the Forum will be held on December 13th at the Hub Cira Centre in Philadelphia. Attendees of Peter's talk will be eligible for ethics CLE credits.